Adewole, Tolulope; Albrecht, Bjorn; Beg, Shaalan; Brawley, Otis; Chang, I-Fen; Daly, Bobby; de Claro, Angelo; Dent, Jennifer; Dickler, Maura; Ene-Obong, Abasi; Fashoyin-Aje, Lola; Finnegan, Justin; Galbraith, Susan; Gospodarowicz, Mary; Gralow, Julie; Haddad, Tufia; Kalidas, Chitkala; Katz, Artur; Kaucic, Karen; Keane, Harriet; Lanasa, Mark; Legos, Jeff; Li, Bob T.; Mills, Jennifer; Oelrich, Stefan; Olopade, Stefan; Palma, John; Pazdur, Richard; Pilarski, Piotr; Qian, Jing; Rudd, Kevin; Shokrpour, Sepideh; Tendler, Craig; Wilson, Matt; Smart, Victoria W.; Wu, Yi-Long; Yan, James; Zhang, Lianshan; Li, Diya; Shen, Johanna; Silverstein, Amy; Abou-Alfa, Ghassan; Anderson, Shelly; Beyrer, Patrick; Carnival, Danielle; Clarke, Stephen; Conneran, Terri; Deangelis, Lisa M.; Diakos, Connie; Diaz, Luis; dos Anjos, Carlos Henrique; Drebin, Jeffrey A.; Eisenmen, Debra; Flannery, Russell; Fredrickson, David; Isbell, James M.; Jones, David R.; Joseph, Adedayo; Kennedy, Caroline; Kingham, T. Peter; Lee, Adrian; Lee, Nancy Y.; Leigh, Lillian; Li, Zhi-Zhong; Liu, An-Wen; Liu, Dazhi; Liu, Si-Yang; Maggie Liu, Si-Yang; Makker, Vicky; Mallafre-Larrosa, Meritxell; Mcbride, Sean; Mestres, Isabel; Mondaca, Sebastian; Nigro, Paulo; Norton, Larry; Oyler, John V.; Pavlakis, Nick; Powell, Simon; Robinson, Bruce; Qin, Yi; Razavi, Pedram; Reis-Filho, Jorge; Rocco, Gaetano; Rudin, Charles M.; Schell, Orville; Scher, Howard I.; Schrag, Deborah; Simon, Greg; Smith, Dorrance; Speece, Morgan; Tu, Hai-Yan; Umar-Sadiq, Aminu; Wang, Bu-Hai; Wheeler, Helen; Xu, Chong-Rui; Yan, Li-Xu; Yang, Fan; Yoon, Byeong; Young, Catharine; Zhang, Jia-Tao; Zhou, Qing

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

CANCER DISCOVERY

IF33.3

2023-12-121

PRE

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

抗生素与接受靶向或免疫治疗的肝细胞癌患者的不良肿瘤结局之间的关联

JHEP REPORTS

IF7.5

2023-06-0119

OAAI

An analysis comparing the geographic distribution of community cancer center providers to CRC prevalence rates among Medicare beneficiaries

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

IF3.4

2023-01-010

PRE

To Adjudicate or Not Adjudicate That Is the Question

JACC: CARDIOONCOLOGY

IF12.8

2022-12-010

The On- and Off-Ramps of Oncology Accelerated Approval

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2022-10-2052

PRE

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

CLINICAL CANCER RESEARCH

IF10.2

2022-08-124

Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials-Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop

JCO GLOBAL ONCOLOGY

IF3

2022-08-015

OAAI

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data

BLOOD CANCER JOURNAL

IF11.6

2022-04-199

OAAI

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition

NATURE MEDICINE

IF50

2022-04-1931

Li, Bob T.; Daly, Bobby; Gospodarowicz, Mary; Bertagnolli, Monica M.; Brawley, Otis W.; Chabner, Bruce A.; Fashoyin-Aje, Lola; de Claro, R. Angelo; Franklin, Elizabeth; Mills, Jennifer; Legos, Jeff; Kaucic, Karen; Li, Mark; The, Lydia; Hou, Tina; Wu, Ting-Hui; Albrecht, Bjorn; Shao, Yi; Finnegan, Justin; Qian, Jing; Shahidi, Javad; Gasal, Eduard; Tendler, Craig; Kim, Geoffrey; Yan, James; Morrow, Phuong Khanh; Fuchs, Charles S.; Zhang, Lianshan; LaCaze, Robert; Oelrich, Stefan; Murphy, Martin J.; Pazdur, Richard; Rudd, Kevin; Wu, Yi-Long

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials

BLOOD ADVANCES

IF7.1

2022-03-1427

OAAI

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

CLINICAL CANCER RESEARCH

IF10.2

2022-03-0831